Cannabinoides endógenos en la enfermedad hepática: muchos dardos para una sola diana

June 3, 2017 | Autor: Vedrana Reichenbach | Categoría: Gastroenterology, Obesity, Inflammation, Apoptosis, Energy Metabolism, Liver diseases, Humans, Portal hypertension, Liver Cirrhosis, Fatty acids, Mice, Blood Pressure, Animals, Liver Fibrosis, Hepatic Stellate Cells, Clinical Sciences, Rats, Monocytes, Liver Disease, Neurosciences, Ascites, CB 1 receptor, Arachidonic Acid, Vascular Resistance, Liver diseases, Humans, Portal hypertension, Liver Cirrhosis, Fatty acids, Mice, Blood Pressure, Animals, Liver Fibrosis, Hepatic Stellate Cells, Clinical Sciences, Rats, Monocytes, Liver Disease, Neurosciences, Ascites, CB 1 receptor, Arachidonic Acid, Vascular Resistance

Share Embed

Laporkan tautan ini

Descripción

Endogenous cannabinoids are ubiquitous lipid-signaling molecules able to partially mimic the actions produced by Δ9-tetrahydrocannabinol, the compound responsible for most of the psychological effects of marijuana. Endocannabinoids are derived from arachidonic acid and are involved in many physiological effects. This family of substances includes anandamide (arachidonylethanolamide), 2-arachydonylglycerol, noladin ether and virodhamine. The interaction of these substances with CB1 and CB2

Lihat lebih banyak...

Cannabinoides endógenos en la enfermedad hepática: muchos dardos para una sola diana

Descripción

Comentarios